Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology.

Dooley KE, Hanna D, Mave V, Eisenach K, Savic RM.

PLoS Med. 2019 Jul 5;16(7):e1002842. doi: 10.1371/journal.pmed.1002842. eCollection 2019 Jul. Review. No abstract available.

2.

Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.

Peloquin CA, Phillips PPJ, Mitnick CD, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Kaur P, Horsburgh CR Jr.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00770-18. doi: 10.1128/AAC.00770-18. Print 2018 Oct.

3.

An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.

Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Horsburgh CR Jr.

Trials. 2017 Nov 25;18(1):563. doi: 10.1186/s13063-017-2292-x.

4.

Evaluation of the microscopic observation drug susceptibility assay for the detection of first- and second-line drug susceptibility for Mycobacterium tuberculosis.

Catanzaro DG, Trollip AP, Seifert M, Georghiou SB, Garfein RS, Rodwell TC, Catanzaro A, Eisenach KD.

Eur Respir J. 2017 Apr 5;49(4). pii: 1602215. doi: 10.1183/13993003.02215-2016. Print 2017 Apr. No abstract available.

5.

Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages.

Stucki D, Brites D, Jeljeli L, Coscolla M, Liu Q, Trauner A, Fenner L, Rutaihwa L, Borrell S, Luo T, Gao Q, Kato-Maeda M, Ballif M, Egger M, Macedo R, Mardassi H, Moreno M, Tudo Vilanova G, Fyfe J, Globan M, Thomas J, Jamieson F, Guthrie JL, Asante-Poku A, Yeboah-Manu D, Wampande E, Ssengooba W, Joloba M, Henry Boom W, Basu I, Bower J, Saraiva M, Vaconcellos SEG, Suffys P, Koch A, Wilkinson R, Gail-Bekker L, Malla B, Ley SD, Beck HP, de Jong BC, Toit K, Sanchez-Padilla E, Bonnet M, Gil-Brusola A, Frank M, Penlap Beng VN, Eisenach K, Alani I, Wangui Ndung'u P, Revathi G, Gehre F, Akter S, Ntoumi F, Stewart-Isherwood L, Ntinginya NE, Rachow A, Hoelscher M, Cirillo DM, Skenders G, Hoffner S, Bakonyte D, Stakenas P, Diel R, Crudu V, Moldovan O, Al-Hajoj S, Otero L, Barletta F, Jane Carter E, Diero L, Supply P, Comas I, Niemann S, Gagneux S.

Nat Genet. 2016 Dec;48(12):1535-1543. doi: 10.1038/ng.3704. Epub 2016 Oct 31.

6.

Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.

Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang'wa B, du Cros P.

Int J Tuberc Lung Dis. 2016 Mar;20(3):290-4. doi: 10.5588/ijtld.15.0490.

7.

Direct Susceptibility Testing of Mycobacterium tuberculosis for Pyrazinamide by Use of the Bactec MGIT 960 System.

Demers AM, Venter A, Friedrich SO, Rojas-Ponce G, Mapamba D, Jugheli L, Sasamalo M, Almeida D, Dorasamy A, Jentsch U, Gibson M, Everitt D, Eisenach KD, Diacon AH.

J Clin Microbiol. 2016 May;54(5):1276-81. doi: 10.1128/JCM.03162-15. Epub 2016 Feb 24.

8.

Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement.

Domínguez J, Boettger EC, Cirillo D, Cobelens F, Eisenach KD, Gagneux S, Hillemann D, Horsburgh R, Molina-Moya B, Niemann S, Tortoli E, Whitelaw A, Lange C; TBNET; RESIST-TB networks.

Int J Tuberc Lung Dis. 2016 Jan;20(1):24-42. doi: 10.5588/ijtld.15.0221. Review.

PMID:
26688526
9.

Distribution and transmission of Mycobacterium tuberculosis complex lineages among children in peri-urban Kampala, Uganda.

Wampande EM, Mupere E, Jaganath D, Nsereko M, Mayanja HK, Eisenach K, Boom WH, Gagneux S, Joloba ML; Tuberculosis Research Unit.

BMC Pediatr. 2015 Sep 30;15:140. doi: 10.1186/s12887-015-0455-z.

10.

A single-nucleotide-polymorphism real-time PCR assay for genotyping of Mycobacterium tuberculosis complex in peri-urban Kampala.

Wampande EM, Hatzios SK, Achan B, Mupere E, Nsereko M, Mayanja HK, Eisenach K, Boom WH, Gagneux S, Joloba ML; Tuberculosis Research Unit.

BMC Infect Dis. 2015 Sep 30;15:396. doi: 10.1186/s12879-015-1121-7.

11.

Performance Comparison of Three Rapid Tests for the Diagnosis of Drug-Resistant Tuberculosis.

Catanzaro A, Rodwell TC, Catanzaro DG, Garfein RS, Jackson RL, Seifert M, Georghiou SB, Trollip A, Groessl E, Hillery N, Crudu V, Victor TC, Rodrigues C, Lin GS, Valafar F, Desmond E, Eisenach K.

PLoS One. 2015 Aug 31;10(8):e0136861. doi: 10.1371/journal.pone.0136861. eCollection 2015.

12.

Phenotypic and genotypic diversity in a multinational sample of drug-resistant Mycobacterium tuberculosis isolates.

Garfein RS, Catanzaro DG, Rodwell TC, Avalos E, Jackson RL, Kaping J, Evasco H, Rodrigues C, Crudu V, Lin SY, Groessl E, Hillery N, Trollip A, Ganiats T, Victor TC, Eisenach K, Valafar F, Channick J, Qian L, Catanzaro A.

Int J Tuberc Lung Dis. 2015 Apr;19(4):420-7. doi: 10.5588/ijtld.14.0488. Erratum in: Int J Tuberc Lung Dis. 2015 Jul;19(7):874. Groessel, E [corrected to Groessl, E].

13.

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.

Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM.

Lancet. 2015 May 2;385(9979):1738-1747. doi: 10.1016/S0140-6736(14)62002-X. Epub 2015 Mar 18.

PMID:
25795076
14.

The Global Consortium for Drug-resistant Tuberculosis Diagnostics (GCDD): design of a multi-site, head-to-head study of three rapid tests to detect extensively drug-resistant tuberculosis.

Hillery N, Groessl EJ, Trollip A, Catanzaro D, Jackson L, Rodwell TC, Garfein RS, Lin SY, Eisenach K, Ganiats TG, Park D, Valafar F, Rodrigues C, Crudu V, Victor TC, Catanzaro A.

Trials. 2014 Nov 6;15:434. doi: 10.1186/1745-6215-15-434.

15.

Evaluation of pyrosequencing for detecting extensively drug-resistant Mycobacterium tuberculosis among clinical isolates from four high-burden countries.

Ajbani K, Lin SY, Rodrigues C, Nguyen D, Arroyo F, Kaping J, Jackson L, Garfein RS, Catanzaro D, Eisenach K, Victor TC, Crudu V, Gler MT, Ismail N, Desmond E, Catanzaro A, Rodwell TC.

Antimicrob Agents Chemother. 2015 Jan;59(1):414-20. doi: 10.1128/AAC.03614-14. Epub 2014 Nov 3.

16.

Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis.

Wallis RS, Dawson R, Friedrich SO, Venter A, Paige D, Zhu T, Silvia A, Gobey J, Ellery C, Zhang Y, Eisenach K, Miller P, Diacon AH.

PLoS One. 2014 Apr 14;9(4):e94462. doi: 10.1371/journal.pone.0094462. eCollection 2014.

17.

What is the most reliable solid culture medium for tuberculosis treatment trials?

Joloba ML, Johnson JL, Feng PJ, Bozeman L, Goldberg SV, Morgan K, Gitta P, Boom HW, Heilig CM, Mayanja-Kizza H, Eisenach KD.

Tuberculosis (Edinb). 2014 May;94(3):311-6. doi: 10.1016/j.tube.2014.03.002. Epub 2014 Mar 19.

PMID:
24698569
18.

How we determined the most reliable solid medium for studying treatment of tuberculosis.

Heilig CM, Feng PJ, Joloba ML, Johnson JL, Morgan K, Gitta P, Boom WH, Mayanja-Kizza H, Eisenach KD, Bozeman L, Goldberg SV.

Tuberculosis (Edinb). 2014 May;94(3):317-22. doi: 10.1016/j.tube.2014.02.006. Epub 2014 Mar 4.

19.

Treatment outcomes of new tuberculosis patients hospitalized in Kampala, Uganda: a prospective cohort study.

Kirenga BJ, Levin J, Ayakaka I, Worodria W, Reilly N, Mumbowa F, Nabanjja H, Nyakoojo G, Fennelly K, Nakubulwa S, Joloba M, Okwera A, Eisenach KD, McNerney R, Elliott AM, Mugerwa RD, Smith PG, Ellner JJ, Jones-López EC.

PLoS One. 2014 Mar 7;9(3):e90614. doi: 10.1371/journal.pone.0090614. eCollection 2014.

20.

A metabolic biosignature of early response to anti-tuberculosis treatment.

Mahapatra S, Hess AM, Johnson JL, Eisenach KD, DeGroote MA, Gitta P, Joloba ML, Kaplan G, Walzl G, Boom WH, Belisle JT.

BMC Infect Dis. 2014 Jan 31;14:53. doi: 10.1186/1471-2334-14-53.

21.

Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay.

Trollip AP, Moore D, Coronel J, Caviedes L, Klages S, Victor T, Romancenco E, Crudu V, Ajbani K, Vineet VP, Rodrigues C, Jackson RL, Eisenach K, Garfein RS, Rodwell TC, Desmond E, Groessl EJ, Ganiats TG, Catanzaro A.

Int J Tuberc Lung Dis. 2014 Feb;18(2):227-32. doi: 10.5588/ijtld.13.0229.

22.

Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations.

Rodwell TC, Valafar F, Douglas J, Qian L, Garfein RS, Chawla A, Torres J, Zadorozhny V, Kim MS, Hoshide M, Catanzaro D, Jackson L, Lin G, Desmond E, Rodrigues C, Eisenach K, Victor TC, Ismail N, Crudu V, Gler MT, Catanzaro A.

J Clin Microbiol. 2014 Mar;52(3):781-9. doi: 10.1128/JCM.02701-13. Epub 2013 Dec 18.

23.

Elucidating emergence and transmission of multidrug-resistant tuberculosis in treatment experienced patients by whole genome sequencing.

Clark TG, Mallard K, Coll F, Preston M, Assefa S, Harris D, Ogwang S, Mumbowa F, Kirenga B, O'Sullivan DM, Okwera A, Eisenach KD, Joloba M, Bentley SD, Ellner JJ, Parkhill J, Jones-López EC, McNerney R.

PLoS One. 2013 Dec 11;8(12):e83012. doi: 10.1371/journal.pone.0083012. eCollection 2013.

24.

Long-term dominance of Mycobacterium tuberculosis Uganda family in peri-urban Kampala-Uganda is not associated with cavitary disease.

Wampande EM, Mupere E, Debanne SM, Asiimwe BB, Nsereko M, Mayanja H, Eisenach K, Kaplan G, Boom HW, Gagneux S, Joloba ML.

BMC Infect Dis. 2013 Oct 17;13:484. doi: 10.1186/1471-2334-13-484.

25.

Comparison of time to positive and colony counting in an early bactericidal activity study of anti-tuberculosis treatment.

Bark CM, Gitta P, Ogwang S, Nsereko M, Thiel BA, Boom WH, Eisenach KD, Joloba ML, Johnson JL.

Int J Tuberc Lung Dis. 2013 Nov;17(11):1448-51. doi: 10.5588/ijtld.13.0063.

PMID:
24125449
26.

Relapse more common than reinfection in recurrent tuberculosis 1-2 years post treatment in urban Uganda.

Luzze H, Johnson DF, Dickman K, Mayanja-Kizza H, Okwera A, Eisenach K, Cave MD, Whalen CC, Johnson JL, Boom WH, Joloba M; Tuberculosis Research Unit.

Int J Tuberc Lung Dis. 2013 Mar;17(3):361-7. doi: 10.5588/ijtld.11.0692.

27.

Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis.

Fennelly KP, Jones-López EC, Ayakaka I, Kim S, Menyha H, Kirenga B, Muchwa C, Joloba M, Dryden-Peterson S, Reilly N, Okwera A, Elliott AM, Smith PG, Mugerwa RD, Eisenach KD, Ellner JJ.

Am J Respir Crit Care Med. 2012 Sep 1;186(5):450-7. doi: 10.1164/rccm.201203-0444OC. Epub 2012 Jul 12.

28.

Evaluation of Capilia TB assay for rapid identification of Mycobacterium tuberculosis complex in BACTEC MGIT 960 and BACTEC 9120 blood cultures.

Muchwa C, Akol J, Etwom A, Morgan K, Orikiriza P, Mumbowa F, Odong PR, Kateete DP, Eisenach KD, Joloba ML.

BMC Res Notes. 2012 Jan 19;5:44. doi: 10.1186/1756-0500-5-44.

29.

A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct.

Mahapatra S, Woolhiser LK, Lenaerts AJ, Johnson JL, Eisenach KD, Joloba ML, Boom WH, Belisle JT.

Antimicrob Agents Chemother. 2012 Jan;56(1):28-35. doi: 10.1128/AAC.05486-11. Epub 2011 Oct 28.

30.

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.

Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, Campbell TB, Eisenach KD, Hafner R, Lennox JL, Makhene M, Swindells S, Villarino ME, Weiner M, Benson C, Burman W; National Institutes of Health; Centers for Disease Control and Prevention.

Am J Respir Crit Care Med. 2011 Oct 15;184(8):972-9. doi: 10.1164/rccm.201105-0827WS.

31.

Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa.

Mac Kenzie WR, Heilig CM, Bozeman L, Johnson JL, Muzanye G, Dunbar D, Jost KC Jr, Diem L, Metchock B, Eisenach K, Dorman S, Goldberg S.

PLoS One. 2011 Apr 11;6(4):e18358. doi: 10.1371/journal.pone.0018358.

32.

Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study.

Jones-López EC, Ayakaka I, Levin J, Reilly N, Mumbowa F, Dryden-Peterson S, Nyakoojo G, Fennelly K, Temple B, Nakubulwa S, Joloba ML, Okwera A, Eisenach KD, McNerney R, Elliott AM, Ellner JJ, Smith PG, Mugerwa RD.

PLoS Med. 2011 Mar;8(3):e1000427. doi: 10.1371/journal.pmed.1000427. Epub 2011 Mar 15.

33.

Time to detection of Mycobacterium tuberculosis as an alternative to quantitative cultures.

Bark CM, Okwera A, Joloba ML, Thiel BA, Nakibali JG, Debanne SM, Boom WH, Eisenach KD, Johnson JL.

Tuberculosis (Edinb). 2011 May;91(3):257-9. doi: 10.1016/j.tube.2011.01.004. Epub 2011 Feb 25.

34.

Secondary attack rate of tuberculosis in urban households in Kampala, Uganda.

Whalen CC, Zalwango S, Chiunda A, Malone L, Eisenach K, Joloba M, Boom WH, Mugerwa R.

PLoS One. 2011 Feb 14;6(2):e16137. doi: 10.1371/journal.pone.0016137.

35.

Rhomboid homologs in mycobacteria: insights from phylogeny and genomic analysis.

Kateete DP, Okee M, Katabazi FA, Okeng A, Asiimwe J, Boom HW, Eisenach KD, Joloba ML.

BMC Microbiol. 2010 Oct 29;10:272. doi: 10.1186/1471-2180-10-272.

36.

The impact of mouse passaging of Mycobacterium tuberculosis strains prior to virulence testing in the mouse and guinea pig aerosol models.

Converse PJ, Eisenach KD, Theus SA, Nuermberger EL, Tyagi S, Ly LH, Geiman DE, Guo H, Nolan ST, Akar NC, Klinkenberg LG, Gupta R, Lun S, Karakousis PC, Lamichhane G, McMurray DN, Grosset JH, Bishai WR.

PLoS One. 2010 Apr 21;5(4):e10289. doi: 10.1371/journal.pone.0010289.

37.

Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to antituberculosis therapy.

Li L, Mahan CS, Palaci M, Horter L, Loeffelholz L, Johnson JL, Dietze R, Debanne SM, Joloba ML, Okwera A, Boom WH, Eisenach KD.

J Clin Microbiol. 2010 Jan;48(1):46-51. doi: 10.1128/JCM.01526-09. Epub 2009 Nov 18.

38.

Comparison of two concentrations of NALC-NaOH for decontamination of sputum for mycobacterial culture.

Peres RL, Maciel EL, Morais CG, Ribeiro FC, Vinhas SA, Pinheiro C, Dietze R, Johnson JL, Eisenach K, Palaci M.

Int J Tuberc Lung Dis. 2009 Dec;13(12):1572-5.

PMID:
19919781
39.

Comparison of rapid tests for detection of rifampicin-resistant Mycobacterium tuberculosis in Kampala, Uganda.

Ogwang S, Asiimwe BB, Traore H, Mumbowa F, Okwera A, Eisenach KD, Kayes S, Jones-López EC, McNerney R, Worodria W, Ayakaka I, Mugerwa RD, Smith PG, Ellner J, Joloba ML.

BMC Infect Dis. 2009 Aug 26;9:139. doi: 10.1186/1471-2334-9-139.

40.

Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.

Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, Gitta P, Okwera A, Mugerwa RD, Alcaneses MR, Quelapio MI, Tupasi TE, Horter L, Debanne SM, Eisenach KD, Boom WH.

Am J Respir Crit Care Med. 2009 Sep 15;180(6):558-63. doi: 10.1164/rccm.200904-0536OC. Epub 2009 Jun 19.

41.

Evaluation of low-colony-number counts of Mycobacterium tuberculosis on solid media as a microbiological marker of cross-contamination.

Ribeiro FK, Lemos EM, Hadad DJ, Leão SC, Viana-Niero C, Dietze R, Johnson JL, Eisenach KD, Palaci M.

J Clin Microbiol. 2009 Jun;47(6):1950-2. doi: 10.1128/JCM.00626-09. Epub 2009 Apr 8.

42.

Clinical strains of Mycobacterium tuberculosis display a wide range of virulence in guinea pigs.

Palanisamy GS, DuTeau N, Eisenach KD, Cave DM, Theus SA, Kreiswirth BN, Basaraba RJ, Orme IM.

Tuberculosis (Edinb). 2009 May;89(3):203-9. doi: 10.1016/j.tube.2009.01.005. Epub 2009 Feb 28.

PMID:
19251482
43.

Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda.

Temple B, Ayakaka I, Ogwang S, Nabanjja H, Kayes S, Nakubulwa S, Worodria W, Levin J, Joloba M, Okwera A, Eisenach KD, McNerney R, Elliott AM, Smith PG, Mugerwa RD, Ellner JJ, Jones-López EC.

Clin Infect Dis. 2008 Nov 1;47(9):1126-34. doi: 10.1086/592252.

44.

Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis.

Dietze R, Hadad DJ, McGee B, Molino LP, Maciel EL, Peloquin CA, Johnson DF, Debanne SM, Eisenach K, Boom WH, Palaci M, Johnson JL.

Am J Respir Crit Care Med. 2008 Dec 1;178(11):1180-5. doi: 10.1164/rccm.200806-892OC. Epub 2008 Sep 11.

45.

Use of in-house PCR for identification of Mycobacterium tuberculosis in BACTEC broth cultures of respiratory specimens.

Gouveia AC, Eisenach KD, Vinhas SA, Ribeiro FK, Peres RL, Dietze R, Hadad DJ, Palaci M.

Mem Inst Oswaldo Cruz. 2008 Jun;103(4):386-91.

46.

Beijing family Mycobacterium tuberculosis strains differ in their intracellular growth in THP-1 macrophages.

Theus S, Eisenach K, Fomukong N, Silver RF, Cave MD.

Int J Tuberc Lung Dis. 2007 Oct;11(10):1087-93.

PMID:
17945065
47.

Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis.

Palaci M, Dietze R, Hadad DJ, Ribeiro FK, Peres RL, Vinhas SA, Maciel EL, do Valle Dettoni V, Horter L, Boom WH, Johnson JL, Eisenach KD.

J Clin Microbiol. 2007 Dec;45(12):4064-6. Epub 2007 Oct 10.

48.

Persistence, not resistance, is the cause of loss of isoniazid effect.

Wallis RS, Palaci M, Eisenach K.

J Infect Dis. 2007 Jun 15;195(12):1870-1; author reply 1872-3. No abstract available.

PMID:
17492604
49.

Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda.

Traore H, Ogwang S, Mallard K, Joloba ML, Mumbowa F, Narayan K, Kayes S, Jones-Lopez EC, Smith PG, Ellner JJ, Mugerwa RD, Eisenach KD, McNerney R.

Ann Clin Microbiol Antimicrob. 2007 Jan 9;6:1.

50.

Introduction of an in-house PCR for routine identification of M. tuberculosis in a low-income country.

Muhumuza J, Asiimwe BB, Kayes S, Mugyenyi R, Whalen C, Mugerwa RD, Boom H, Eisenach KD, Joloba ML.

Int J Tuberc Lung Dis. 2006 Nov;10(11):1262-7.

PMID:
17131786

Supplemental Content

Loading ...
Support Center